Add-on effect of Qinbei Qingfei Yiqi granules for ventilator-associated pneumonia in intensive care units: a randomized controlled trial.
To evaluate the add-on effect of Qinbei Qingfei Yiqi (QBQFYQ) granules for ventilator-associated pneumonia (VAP) in non-infectious critically ill patients. In this randomized controlled trial, 80 non-infectious critically ill patients undergoing mechanical ventilation in the intensive care unit (ICU) were randomly divided into two groups: those receiving QBQFYQ granules plus usual treatment (experimental group, n = 50) and those receiving only the usual treatment (control group, n = 30). The main outcome measures were VAP rate, time of VAP occurrence, duration of mechanical ventilation, and length of ICU stay. Interleukin-6 (IL-6), C-reactive protein (CRP), and T-lymphocyte (CD4+, CD8+, and CD4+/CD8+ ratio) serum levels were also evaluated before and after treatment. Compared with the control group treatment QBQFYQ administration significantly reduced the duration of mechanical ventilation [(9.58 ± 3.14) vs (12.52 ± 4.33) days] and length of ICU stay [(14.57 ± 3.72) vs (17.82 ± 5.24) days] and delayed VAP occurrence [(4.31 ± 0.86) vs (2.43 ± 0.27) days]. Additionally, CRP and IL-6 serum levels and CD4+/CD8+ ratio were significantly lower in the experimental group (P < 0.05) than in the control group. However, there were no significant differences in hospital mortality rate (30.0% vs 33.3% ) and adverse events (4.0% vs 6.7%). adverse events (4.0% vs 6.7%). QBQFYQ delays the time of VAP occurrence and shortens the duration of mechanical ventilation in non-infectious critically ill patients, possibly through anti-inflammatory and immunomodulatory mechanisms.